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COVID‐19 (coronavirus disease 2019) is sweeping across the globe. Most patients have mild‐to‐moderate symptoms, but a subgroup will become severely ill. Sepsis, respiratory failure, and acute respiratory distress syndrome (ARDS) are common complications of the disease [1](#art41285-bib-0001){ref-type="ref"}. Factors associated with admission to the intensive care unit and death include older age, comorbid conditions, elevated body mass index, lymphopenia, and elevated blood levels of transaminases, lactate dehydrogenase (LDH), [d]{.smallcaps}‐dimer, ferritin, and soluble interleukin‐2 receptor (sIL‐2R) [1](#art41285-bib-0001){ref-type="ref"}, [2](#art41285-bib-0002){ref-type="ref"}, [3](#art41285-bib-0003){ref-type="ref"}, [4](#art41285-bib-0004){ref-type="ref"}.

This constellation of features is reminiscent of a family of syndromes broadly gathered under the umbrella of cytokine storm syndrome, in which hyperinflammation and multiorgan disease arise through excessive cytokine release from uncontrolled immune activation (Figure [1](#art41285-fig-0001){ref-type="fig"}). Rheumatologists face this foe regularly in systemic juvenile idiopathic arthritis (JIA), adult‐onset Still\'s disease, and systemic lupus erythematosus, among other diseases. Macrophage activation syndrome (MAS), one form of cytokine storm syndrome, develops in at least 10% of patients with systemic JIA. Compared to systemic JIA patients without MAS, those with this complication are more likely to carry heterozygous variants in genes mediating the release of cytotoxic granules from natural killer (NK) cells and CD8+ T cells; biallelic mutations of these genes cause an inherited form of cytokine storm syndrome termed familial hemophagocytic lymphohistiocytosis (HLH). Reduced cytotoxicity impairs clearance of infected cells and elimination of activated macrophages, leading to massive release of proinflammatory mediators. One of these mediators, IL‐6, further impairs NK cell function. Patients present with rapid onset of fever, cytopenias, coagulopathy, elevated transaminase levels, hyperferritinemia, and multiorgan dysfunction. Historically, the cornerstones of treatment were glucocorticoids, intravenous immunoglobulin (IVIG), and cyclosporine. Despite these interventions, mortality was as high as 20%. Identification of key mediators driving MAS---including IL‐1β, IL‐6, IL‐18, and interferon‐γ (IFNγ)---have inaugurated a new era of cytokine neutralization, potentially enabling a marked reduction in mortality [5](#art41285-bib-0005){ref-type="ref"}, [6](#art41285-bib-0006){ref-type="ref"}.

![The family of conditions characterized by cytokine storm. Malig. = malignancy; Assoc. = associations; SJIA = systemic juvenile idiopathic arthritis; MAS = macrophage activation syndrome; CRS = cytokine release syndrome; ARDS = acute respiratory distress syndrome; EBV = Epstein‐Barr virus; HLH = hemophagocytic lymphohistiocytosis.](ART-9999-na-g001){#art41285-fig-0001}

Herpes family viruses (e.g., Epstein‐Barr virus) and influenza are major triggers of cytokine storm, both in systemic JIA and in patients without a preexisting immunologic diagnosis. As in systemic JIA--related MAS, the inflammatory cytokines IFNγ and IL‐18 are key mediators of hyperinflammation in a murine model of repeated Toll‐like receptor 9 stimulation, which mimics severe viral infection [6](#art41285-bib-0006){ref-type="ref"}. In one study of patients without underlying rheumatic disease who died of H1N1 influenza, 81% displayed features of cytokine storm, and 36% carried pathologic variants in the cytolytic pathway [7](#art41285-bib-0007){ref-type="ref"}. Treatments effective in systemic JIA--related MAS can benefit patients with cytokine storm triggered by infections [8](#art41285-bib-0008){ref-type="ref"}, [9](#art41285-bib-0009){ref-type="ref"}. Post hoc analysis of a phase III randomized controlled trial of anakinra (recombinant IL‐1 receptor antagonist) in sepsis showed that patients with coagulopathy and elevated transaminase levels exhibited better survival with IL‐1 blockade than with standard of care (65% versus 35%; hazard ratio for death 0.28, *P* = 0.007) [10](#art41285-bib-0010){ref-type="ref"}. Similarly, IL‐6 blockade is effective in treating the related cytokine release syndrome from chimeric antigen receptor T cell (CAR‐T) therapy [11](#art41285-bib-0011){ref-type="ref"}.

Hyperinflammation in COVID‐19 is not MAS, and it may even be distinct from other forms of viral‐induced cytokine storm, in that ferritin elevation is modest and severe end‐organ disease is focused on the lung. Some patients with COVID‐19 may simply have "garden‐variety" ARDS associated with the tropism of the virus for the lung. However, critically ill patients with COVID‐19 often demonstrate features suggestive of cytokine storm, including fever, characteristic changes in laboratory study findings, and ARDS. Lung tissue from patients with severe acute respiratory syndrome (SARS), the etiology of which has been attributed to a related coronavirus, showed hemophagocytosis---a central pathologic feature of cytokine storm---in 2 of 6 patients who succumbed to the disease [12](#art41285-bib-0012){ref-type="ref"}. Patients with SARS also exhibited high levels of IFNγ and IL‐18, which are particularly important in cytokine storm syndrome [13](#art41285-bib-0013){ref-type="ref"}. Thus, the host\'s immune response and development of tissue‐focused inflammation in the lung likely plays an important role in COVID‐19.

These considerations suggest that, beyond antiviral therapy and supportive care, it will be important to monitor hospitalized patients with COVID‐19 for evidence of cytokine storm. Impending hyperinflammation can manifest as cytopenias (thrombocytopenia and lymphopenia), coagulopathy (low platelet and fibrinogen levels, and elevated [d]{.smallcaps}‐dimer levels), tissue damage/hepatitis (elevated LDH, aspartate aminotransferase, and alanine aminotransferase levels), and macrophage/hepatocyte activation (elevated ferritin levels) (Table [1](#art41285-tbl-0001){ref-type="table"} and [Supplementary Table 1](#art41285-sup-0001){ref-type="supplementary-material"}, available on the *Arthritis & Rheumatology* web site at <http://onlinelibrary.wiley.com/doi/10.1002/art.41285/abstract>). Cytokine measurement is a theoretically appealing approach, but IFNγ and IL‐1β are not easily assessed in the peripheral blood and IL‐6 levels have not yet been proven consistently predictive of poor outcomes. CXCL9, a stable chemokine, is a useful surrogate for IFNγ activity in MAS, as is adenosine deaminase 2 (ADA‐2); however, real‐time measurement of CXCL9 is not commonly available and ADA‐2 testing remains available largely on a research basis. Experience suggests that trends in laboratory test findings, rather than threshold values, will be most informative. In a patient with COVID‐19 who develops lymphopenia, worsening coagulopathy, hepatitis, and rising ferritin levels, it may make sense to target immune hyperactivity before end‐organ manifestations, such as ARDS, ensue.

###### 

Biomarkers of cytokine storm syndrome (CSS)[a](#art41285-note-0005){ref-type="fn"}

  Biomarker                               Biology                                          Status in hyperinflammation                                      Status in COVID‐19                        Test availability
  --------------------------------------- ------------------------------------------------ ---------------------------------------------------------------- ----------------------------------------- -------------------
  CRP                                     Hepatic release in response to IL‐6              Nonspecific, useful for monitoring, blunted by IL‐6 blockade     Associated with severity, ARDS            A
  Complete blood cell count               Multifactorial cytopenias                        May be indicative of CSS (especially thrombocytopenia)           Associated with severity, ARDS            A
  ↑ [d]{.smallcaps}‐dimer, ↓ fibrinogen   Fibrin degradation product, reflective of DIC    May be indicative of active CSS                                  Associated with severity, ARDS            A
  LDH, AST, ALT                           Tissue injury, hepatitis                         May be indicative of active CSS                                  Associated with severity, ARDS            A
  Ferritin                                Macrophage/hepatocyte activation                 Integral part of CSS diagnosis, predictive of sepsis mortality   Associated with severity, ARDS            A
  Ferritin:ESR ratio                      ESR falls with fibrinogen consumption            Higher specificity than ferritin alone                           Not assessed                              A
  Procalcitonin                           Adipokine                                        Nonspecific, useful for monitoring                               Variably associated with severity, ARDS   A, S
  IL‐2Ra (CD25)                           Cleaved from T cells by inflammatory proteases   Part of HLH diagnostic criteria, useful for monitoring           Associated with severity                  S
  IL‐6                                    Pleiotropic inflammatory cytokine                Elevated, nonspecific                                            Associated with severity                  S
  Neopterin                               Metabolite of GTP induced by IFNγ                Elevated in blood and CSF                                        Not assessed                              S
  IFNγ                                    Classic type 1/Th1 cytokine                      Elevated, but poor dynamic range                                 Elevated compared with healthy control    S, R
  CXCL9                                   Chemokine induced by IFNγ                        Elevated in most CSS, useful for monitoring                      Not assessed                              S
  IL‐1β                                   Inflammasome‐activated                           Elevated, but poor dynamic range                                 Variably elevated with severity           S, R
  IL‐18                                   Inflammasome‐activated, IFNγ inducing            Very high levels may indicate MAS, not useful for monitoring     Not assessed                              S
  ADA‐2                                   Released by IFNγ‐activated monocytes             Elevated in most CSS, useful for monitoring                      Not assessed                              S, R
  S100 proteins                           Neutrophil/monocyte activation                   Elevated in active systemic JIA and MAS, and in some ARDS        Not assessed                              S, R
  CD163                                   Cleaved from tissue macrophages                  Elevated in active systemic JIA and MAS, and in ARDS             Not assessed                              S, R

Relevant citations are provided in Supplementary Table [1](#art41285-sup-0001){ref-type="supplementary-material"} (available on the *Arthritis & Rheumatology* web site at <http://onlinelibrary.wiley.com/doi/10.1002/art.41285/abstract>). COVID‐19 = coronavirus disease 2019; CRP = C‐reactive protein; IL‐6 = interleukin‐6; ARDS = acute respiratory distress syndrome; A = widely available; DIC = disseminated intravascular coagulation; LDH = lactate dehydrogenase; AST = aspartate aminotransferase; ALT = alanine aminotransferase; ESR = erythrocyte sedimentation rate; S = typically send‐out; IL‐2Ra = IL‐2 receptor antagonist; HLH = hemophagocytic lymphohistiocytosis; IFNγ = interferon‐γ; CSF = cerebrospinal fluid; R = may be available only on a research basis; MAS = macrophage activation syndrome; ADA‐2 = adenosine deaminase 2; JIA = juvenile idiopathic arthritis.
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The US Centers for Disease Control and Prevention provided an unqualified recommendation against the use of glucocorticoids for the treatment of COVID‐19, based on prior experience with influenza, SARS, and coronavirus‐induced Middle East respiratory syndrome (MERS) [14](#art41285-bib-0014){ref-type="ref"}. However, a Cochrane review of glucocorticoids as adjunctive therapy in influenza found that the evidence was of low quality, largely because of confounding by indication [15](#art41285-bib-0015){ref-type="ref"}. The literature with regard to glucocorticoids in patients with MERS and SARS has reported similar findings, although some data suggest that glucocorticoids could delay viral clearance [16](#art41285-bib-0016){ref-type="ref"}. Importantly, these data reflect treatment of "all comers" with influenza, MERS, or SARS, rather than therapy targeted to patients with evidence of hyperinflammation. Of note, in one COVID‐19 case series, the mortality rate was lower in patients with ARDS who were treated with methylprednisolone compared with those who did not receive glucocorticoids (46% versus 62%; hazard ratio for death 0.38, *P* = 0.003), although, again, the possibility of confounding by indication is difficult to exclude [2](#art41285-bib-0002){ref-type="ref"}.

Experience from hyperinflammation in HLH, MAS, and cytokine release syndrome suggests that early intervention is essential to avoiding life‐threatening tissue damage. In patients with COVID‐19 who exhibit evidence of cytokine storm, treatment with glucocorticoids, IVIG, and/or anticytokine therapies should be considered, with the aim of reverting hyperinflammation before ARDS occurs (Table [2](#art41285-tbl-0002){ref-type="table"} and Supplementary Table [2](#art41285-sup-0001){ref-type="supplementary-material"}, available on the *Arthritis & Rheumatology* web site at <http://onlinelibrary.wiley.com/doi/10.1002/art.41285/abstract>) [8](#art41285-bib-0008){ref-type="ref"}, [17](#art41285-bib-0017){ref-type="ref"}. Glucocorticoids remain a key first‐line option, and clinical trials are urgently needed to test their efficacy and to identify optimal dosing, especially given the clear advantage of glucocorticoids in worldwide availability and cost. IL‐1 blockade has shown particular promise as a treatment for cytokine storm syndrome, and high‐dose regimens are safe even in the context of overt sepsis [5](#art41285-bib-0005){ref-type="ref"}, [10](#art41285-bib-0010){ref-type="ref"}. Tocilizumab (anti--IL‐6 receptor) is effective in cytokine release syndrome associated with CAR‐T therapy, a syndrome notably reminiscent of COVID‐19 in that many patients develop ARDS [11](#art41285-bib-0011){ref-type="ref"}. Emapalumab (anti‐IFNγ) is approved by the US Food and Drug Administration for the treatment of HLH and may be effective in MAS. JAK inhibition appears promising; however, the safety of these medications in severe viral infection remains unknown.

###### 

Treatments for cytokine storm syndrome of potential utility in severe COVID‐19[a](#art41285-note-0006){ref-type="fn"}

  Intervention                                                             Biology                                                  Experience in hyperinflammation                                                                                 Experience in COVID‐19                                                                   Potential likelihood of impairing viral suppression/clearance[b](#art41285-note-0007){ref-type="fn"}   Concerns
  ------------------------------------------------------------------------ -------------------------------------------------------- --------------------------------------------------------------------------------------------------------------- ---------------------------------------------------------------------------------------- ------------------------------------------------------------------------------------------------------ ----------------------------------------------------------------------
  Glucocorticoids (\<2 mg/kg/day)[c](#art41285-note-0008){ref-type="fn"}   Transcriptional regulation via glucocorticoid receptor   Mainstay of treatment                                                                                           May improve outcomes in ARDS (ChiCTR2000029386)[d](#art41285-note-0009){ref-type="fn"}   ++                                                                                                     Hypertension, immunosuppression, metabolic changes, mood alterations
  Glucocorticoids (\>250 mg/day)[c](#art41285-note-0008){ref-type="fn"}    Transcriptional regulation via glucocorticoid receptor   Commonly used during initiation                                                                                 May improve outcomes in ARDS (ChiCTR2000029386)[d](#art41285-note-0009){ref-type="fn"}   ++                                                                                                     Hypertension, immunosuppression, metabolic changes, mood alterations
  Cyclosporine, tacrolimus                                                 Inhibit calcineurin‐mediated lymphocyte activation       Case reports/small series in MAS, part of HLH treatment protocol                                                Theoretical                                                                              ++                                                                                                     Hypertension, renal failure, immunosuppression
  Anakinra                                                                 Block IL‐1 signaling                                     Re‐analysis of sepsis trials, large series in MAS and HLH (NCT02780583)                                         NCT04324021                                                                              \+                                                                                                     Rare transaminitis, neutropenia, eosinophilia
  Sarilumab, tocilizumab                                                   Block IL‐6 signaling                                     CAR‐T cytokine release syndrome, case reports, ongoing clinical trials[e](#art41285-note-0010){ref-type="fn"}   NCT04322773, NCT04317092, NCT04320615, NCT04306705, NCT04324073, NCT04315298             \+                                                                                                     Cytopenias, immunosuppression
  Emapalumab                                                               Neutralize IFNγ                                          Refractory familial HLH, other case reports, ongoing trials[e](#art41285-note-0010){ref-type="fn"}              NCT04324021                                                                              \+                                                                                                     Immunosuppression
  JAK inhibitors                                                           Inhibit JAK/STAT pathway cytokines                       Case reports, ongoing clinical trials                                                                           NCT04320277, NCT04321993                                                                 +++                                                                                                    Cytopenias, immunosuppression
  Cytokine adsorption                                                      Remove from circulation                                  Case reports                                                                                                    NCT04324528                                                                              Minimal                                                                                                Central line access
  IVIG                                                                     Unclear mechanism                                        Case reports                                                                                                    Theoretical                                                                              Minimal                                                                                                Hypertension, hemolysis
  Therapeutic plasma exchange                                              Remove cytokines/chemokines/DAMPs, replace factors       Case reports                                                                                                    Theoretical                                                                              Minimal                                                                                                Central line access

Relevant citations are provided in Supplementary Table [2](#art41285-sup-0001){ref-type="supplementary-material"} (available on the *Arthritis & Rheumatology* web site at <http://onlinelibrary.wiley.com/doi/10.1002/art.41285/abstract>). COVID‐19 = coronavirus disease 2019; ARDS = acute respiratory distress syndrome; MAS = macrophage activation syndrome; HLH = hemophagocytic lymphohistiocytosis; IL‐1 = interleukin‐1; CAR‐T = chimeric antigen receptor T cell therapy; IFNγ = interferon‐γ; IVIG = intravenous immunoglobulin; DAMPs = damage‐associated molecular patterns.

+, ++, and +++ indicate low, moderate, and high likelihood of impairment.

In methylprednisolone equivalent doses.

Dosage unclear.
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Clinical trials are currently enrolling patients with COVID‐19 to study the safety and efficacy of glucocorticoids and cytokine blockade strategies utilizing neutralization of IL‐1, IL‐6, and IFNγ (Table [2](#art41285-tbl-0002){ref-type="table"}). Absent the opportunity to enroll patients in one of these studies, we would consider immunosuppression in patients with COVID‐19 who have incipient cytokine storm. Ideally, treatment decisions will be undertaken with the help of a multidisciplinary team familiar with the triggers, manifestations, and treatments of cytokine storm [17](#art41285-bib-0017){ref-type="ref"}. Glucocorticoids will likely be useful. Cytokine blockers may play an important role as well, while we must remain cognizant of the ongoing need for these medications in patients with chronic rheumatologic conditions. Unfortunately, many patients with COVID‐19 will become critically ill before high‐quality evidence of treatment efficacy is available, leaving us to extrapolate as best we can from the available evidence and from current clinical experience in cytokine storm syndromes.
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